The mechanism of 3-methoxy puerarin on decreasing the cerebral ischemia-reperfusion injury in rats.
The aim of this study was to explore the mechanism of 3-methoxy puerarin on decreasing the cerebral ischemia-reperfusion injury in rats. Before the model of cerebral ischemia-reperfusion injury was made, the rats in one group (3-methoxy puerarin group, 3-MP group) were pretreated with 3-methoxy puerarin (100 mg/kg) by gavageing two times per day for seven days. At an hour before operation, the rats in the 3-MP group were additionally given 3-methoxy puerarin by gavageing once. The level of prostacyclin (PGI2) and the expression of endothelin-1 (ET-1) mRNA in cerebral tissue, the activity of plasma tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) were measured. Cerebral tissue pathologic changes were also observed. The levels of PGI2 in cerebral tissue and the activity of plasma t-PA in 3-MP group were significantly higher than those in the group of cerebral ischemia-reperfusion injury (CIRI group) (p<0.01). The activity of plasma PAI and the expression of ET-1 mRNA in cerebral tissue in 3-MP group were significantly lower than those in CIRI group (p<0.01). The cerebral tissue pathologic changes were significant in CIRI group, which were significantly ameliorated in the 3-MP group. The study showed, in the rat model of cerebral ischemia-reperfusion injury, 3-methoxy puerarin can not only increase the level of PGI2 in cerebral tissue and the activity of plasma t-PA, but also inhibit the activity of plasma PAI and the expression of ET-1 mRNA in cerebral tissue. Those findings might be the mechanisms behind the protecting effects of 3-methoxy puerarin on the cerebral ischemia-reperfusion injury.
Zhao
Tongfeng
T
Department of Traditional Chinese Medicine, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China 310009.
Han
Jin
J
Chen
Yueqing
Y
Wan
Haitong
H
Bie
Xiaodong
X
D000818:Animals; D001921:Brain / Q000378:metabolism*; D004195:Disease Models, Animal; D019332:Endothelin-1 / Q000235:genetics / Q000378:metabolism; D011464:Epoprostenol / Q000235:genetics / Q000378:metabolism; D007529:Isoflavones / Q000627:therapeutic use*; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion; D015427:Reperfusion Injury / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000378:metabolism; D014665:Vasodilator Agents / Q000627:therapeutic use*
D019332:Endothelin-1; D007529:Isoflavones; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D014665:Vasodilator Agents; D011464:Epoprostenol; D010959:Tissue Plasminogen Activator; C033607:puerarin